Literature DB >> 19924528

Association of rare MSH6 variants with familial breast cancer.

Marijke Wasielewski1, Muhammad Riaz, Joyce Vermeulen, Ans van den Ouweland, Ineke Labrijn-Marks, Renske Olmer, Linda van der Spaa, Jan G M Klijn, Hanne Meijers-Heijboer, Dennis Dooijes, Mieke Schutte.   

Abstract

Germline mutations in the mismatch repair genes MLH1, MSH2, MSH6, and PMS2 predispose to Lynch syndrome (also known as hereditary non-polyposis colorectal cancer). Recently, we have shown that the CHEK2 1100delC mutation also is associated with Lynch syndrome/Lynch syndrome-associated families albeit in a polygenic setting. Two of the ten CHEK2 1100delC positive Lynch syndrome families additionally carried a pathogenic MLH1 or MSH6 mutation, suggesting that mutations in mismatch repair genes may be involved in CHEK2 1100delC-associated cancer phenotypes. A phenotype of importance is hereditary breast and colorectal cancer (HBCC), with the CHEK2 1100delC mutation present in almost one-fifth of the families-again in a polygenic setting. In order to evaluate the involvement of MSH6 in polygenic CHEK2 cancer susceptibility, we, here, have analyzed the entire MSH6 coding sequence for genetic alterations in 68 HBCC breast cancer families. Rare MSH6 variants, with population frequencies below 1%, were identified in 11.8% of HBCC breast cancer families, whereas the same variants were identified in only 1.5% of population controls, suggesting that rare MSH6 variants are associated with HBCC breast cancer (P < or = 0.00001). However, screening of the entire MSH6 coding sequence in 68 non-HBCC breast cancer families showed a similar association (8.8 vs. approximately 1.4% in controls, P < or = 0.001), suggesting that rare MSH6 variants are not confined to HBCC breast cancer. Together, our data suggest that rare MSH6 variants may predispose to familial breast cancer. However, none of the rare MSH6 variants are obviously pathogenic, suggesting that a more subtle disease mechanism may operate in breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924528     DOI: 10.1007/s10549-009-0634-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.

Authors:  Carin R Espenschied; Holly LaDuca; Shuwei Li; Rachel McFarland; Chia-Ling Gau; Heather Hampel
Journal:  J Clin Oncol       Date:  2017-05-17       Impact factor: 44.544

Review 2.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

3.  Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.

Authors:  Hsiao-Mei Lu; Shuwei Li; Mary Helen Black; Shela Lee; Robert Hoiness; Sitao Wu; Wenbo Mu; Robert Huether; Jefferey Chen; Srijani Sridhar; Yuan Tian; Rachel McFarland; Jill Dolinsky; Brigette Tippin Davis; Sharon Mexal; Charles Dunlop; Aaron Elliott
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

Review 4.  Phenotype-genotype correlation in familial breast cancer.

Authors:  Ana Cristina Vargas; Jorge S Reis-Filho; Sunil R Lakhani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-12       Impact factor: 2.673

5.  MUTYH gene variants and breast cancer in a Dutch case–control study.

Authors:  Astrid A Out; Marijke Wasielewski; Petra E A Huijts; Ivonne J H M van Minderhout; Jeanine J Houwing-Duistermaat; Carli M J Tops; Maartje Nielsen; Caroline Seynaeve; Juul T Wijnen; Martijn H Breuning; Christi J van Asperen; Mieke Schutte; Frederik J Hes; Peter Devilee
Journal:  Breast Cancer Res Treat       Date:  2012-07       Impact factor: 4.872

6.  Differential analysis of mutations in the Jewish population and their implications for diseases.

Authors:  Yaron Einhorn; Daphna Weissglas-Volkov; Shai Carmi; Harry Ostrer; Eitan Friedman; Noam Shomron
Journal:  Genet Res (Camb)       Date:  2017-05-15       Impact factor: 1.588

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.